ESMO 2016 highlights in gastric cancer: GOLD, PHOENIX-GC, MRC ST03

Speaker: Elisabeth Smith

Elisabeth Smyth discusses the key findings from the trials presented at ESMO 2016: the studies range from testing olaparib in advanced gastric cancer progressed following 1st-line therapy, intraperitoneal chemotherapy for peritoneal metastasis from gastric cancer, and lapatinib feasibility study in HER-2 positive gastric, oesophagogastric junctional or lower oesophageal adenocarcinoma.

Discussion Points

  1. Rationale for the studies
  2. Key study findings
  3. Practice perspective                                                               
  4. Future research opportunities


LBA25 - Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study

616PD - Phase III study comparing intraperitoneal paclitaxel plus S-1/paclitaxel with S-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial

LBA26 - A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948)